Pharsight

Minivelle patents expiration

MINIVELLE's oppositions filed in EPO
MINIVELLE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9724310 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

US8231906 NOVEN Transdermal estrogen device and delivery
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730900 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

US9833419 NOVEN Transdermal estrogen device and delivery
Jul, 2028

(4 years from now)

Minivelle is owned by Noven.

Minivelle contains Estradiol.

Minivelle has a total of 4 drug patents out of which 0 drug patents have expired.

Minivelle was authorised for market use on 29 October, 2012.

Minivelle is available in film, extended release;transdermal dosage forms.

Minivelle can be used as a method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900.

The generics of Minivelle are possible to be released after 04 July, 2030.

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 October, 2012

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of MINIVELLE before it's drug patent expiration?
More Information on Dosage

MINIVELLE family patents

Family Patents